Loading
Cancer, Hypoxia, and Metabolism / Nanoplatforms for Cancer Theranostics · Journal article
Oncology Reviews · August 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review examining the mechanistic role of acidosis in cancer progression and surveying nanotechnology-based and pH-responsive drug delivery approaches. It does not report original experimental or clinical data, efficacy outcomes, or comparative results, and therefore cannot support clinical practice decisions.
Journal article.
Acidosis is described as a pivotal factor in somatic cancer evolution and malignancy progression Mechanisms reviewed include enhanced invasion and metastasis, chemoresistance, immune suppression, and metabolic reprogramming Small-molecule and antibody-based therapies targeting pH regulation are briefly examined
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review synthesizing mechanistic concepts and emerging technologies without reporting original data, clinical outcomes, or comparative evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Far from being a mere epiphenomenon, acidosis is a pivotal factor in the somatic evolution of cancer and its progression toward malignancy. This review provides an inclusive overview of the mechanisms by which acidosis induces and selects for malignant phenotypes. We analyze enhanced invasion and metastasis, chemoresistance, immune surveillance suppression, and metabolic reprogramming. We also briefly examine the clinical development of small-molecule and antibody-based therapies targeting pH regulation. Furthermore, this review outlines various drug delivery and therapeutic systems that respond to extracellular and/or intracellular tumor pH, highlighting the advantages of nanomaterials in precision cancer therapy. With advances in artificial intelligence, nanotechnology is poised to expedite the screening of pH-responsive systems for preclinical research, promoting the development of personalized therapies and the mitigation of adverse reactions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.